30
Participants
Start Date
May 21, 2024
Primary Completion Date
November 1, 2025
Study Completion Date
October 1, 2026
CELZ-201-DDT
Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Placebo
Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
RECRUITING
Spine and Wellness Centers of America, Aventura
Lead Sponsor
Creative Medical Technology Holdings Inc
INDUSTRY